Context No head-to-head clinical trials compare contemporary first-line therapies for
metastatic renal cell carcinoma (mRCC). A network meta-analysis provides an approach for
quantitative analysis. Objective To indirectly compare the efficacy and safety of first-line
treatments for mRCC in the intention-to-treat (ITT) population and by clinical risk group.
Evidence acquisition An updated systematic review from database inception to February 17,
2019 identified all parallel-group randomized controlled trials assessing first-line therapy for …